HSD17B13 and liver cancer: Using fixed-effect model, we found that patients with HSD17B13 rs72613567: TA allelic variant are less likely to develop liver cancer under allelic model: TA vs T OR = 0.766, 95% CI = 0.682–0.860, P = 0.000 (Fig. 2).